Results:The initial weekly dose of roxadustat averaged 261 mg, corresponding to approximately 4,000 JPY/week-significantly higher than EPO ( 2,600 JPY/week).The dose gradually declined over the first 50 weeks, followed by an accelerated reduction beyond 60 weeks.After 100 weeks, the average dose and cost decreased to 65% of the initial level.GNRI slightly declined (92 12.4 87 8.9), and CRP rose modestly (0.3 0.14 0.8 0.14 mg/dL), neither reaching statistical significance.No severe adverse events were reported.Conclusion: Long-term treatment with roxadustat demonstrated progressive dose and cost reductions comparable to EPO over a 100-week period.These findings suggest sustained hematopoietic efficacy with potential cost-saving benefits in HD patients.Further studies are warranted to elucidate the underlying mechanisms contributing to long-term dose optimization beyond nutritional or inflammatory influences.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Yang et al. (Wed,) studied this question.